MSACL 2019 US Abstract

Immunoassays in Multiplex for Biomarker Discovery and Validation

Dr. Thomas O Joos
NMI Natural and Medical Sciences Institute at the University of Tübingen

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Thomas O. Dr. Joos (Presenter) NMI at the University of Tuebingen

Presenter Bio: Dr. Thomas Joos joined 1998 NMI at the University of Tuebingen heading the department of biochemistry. Since 2013 he is the deputy managing director. His research is focused on multiplexed immunoassays for biomarker research and diagnostic applications.
Dr. Joos studied Biochemistry at the University of Tuebingen. He performed his Ph.D. degree in 1995 on integrin‐alpha5 during early embroygenesis of Xenopus laevis with Prof. Peter Hausen at the Max‐Planck‐Institute of Developmental Biology.
Dr. Joos is a member of the editorial board of Drug Discovery Today, Proteomics, and Expert Review of Proteomics. He is a member of the scientific advisory board of the Plasma Proteome Institute Washington, DC, USA, and of Myriad‐RBM, Austin, TX, USA. He is the director of Strategic Alliances at HOT Screen, Reutlingen, GErmany and he is co-founder of SIGNATOPE, Reutlingen, Germany.

Relevant Financial Disclosures (within past 24 months) Grant/Research Support NMI granted projects from Pharma Companies, including Bayer, Roche, Merck Serono, BI Committee/Board/Advisory Board SIGNATOPE GmbH Stock/Bonds Luminex Salary HOT Screen GmbH, Reutlingen, Germany Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Conflict mitigation IN PROCESS.

Array-based assay systems allow the analysis of hundreds of molecular parameters in a single experiment. Within the last decade protein microarray technologies achieved robust analytical performance and enable to screen for a multitude of parameters using minimal amounts of sample material.
There are a variety of technologies and methods available to address assay requirements in terms of covering analyte concentration, sample variety and sample origin. An overview of classical and emerging immunoassays ranging from sandwich-, mass spectrometry-, bead array-, and digital array-based immunoassays will be presented. Advantages of the different methods will be demonstrated by addressing biological issues for immunological screening approaches and drug-induced injury biomarker research, toxicology and oncology.